May 8, 2017 08:37 AM EDT

Nixed by the FDA, TherapeuticsMD is now planning a long-shot bid to reverse the decision

John Carroll

Editor & Founder

TherapeuticsMD already flagged that the FDA was about to reject its application for TX-004HR, a proposed new therapy to treat vaginal pain during intercourse …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Nixed by the FDA, TherapeuticsMD is now planning a long-shot bid to reverse the decision

John Carroll

Editor & Founder

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

FDA vaccine chief Peter Marks pledges to stay as long as he's welcome

At Jefferies, all that manufacturers want to talk about is GLP-1s

Are programs with compounded GLP-1s safe for your population?

Nixed by the FDA, Ther­a­peu­tic­sMD is now plan­ning a long-shot bid to re­verse the de­ci­sion

John Carroll

Editor & Founder

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Nixed by the FDA, TherapeuticsMD is now planning a long-shot bid to reverse the decision

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

FDA vaccine chief Peter Marks pledges to stay as long as he's welcome

At Jefferies, all that manufacturers want to talk about is GLP-1s

Are programs with compounded GLP-1s safe for your population?